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Synapse loss is an early feature shared by many neurodegenerative diseases, and
it represents the major correlate of cognitive impairment. Recent studies reveal that
microglia and astrocytes play a major role in synapse elimination, contributing to network
dysfunction associated with neurodegeneration. Excitatory and inhibitory activity can be
affected by glia-mediated synapse loss, resulting in imbalanced synaptic transmission
and subsequent synaptic dysfunction. Here, we review the recent literature on the
contribution of glia to excitatory/inhibitory imbalance, in the context of the most
common neurodegenerative disorders. A better understanding of the mechanisms
underlying pathological synapse loss will be instrumental to design targeted therapeutic
interventions, taking in account the emerging roles of microglia and astrocytes in
synapse remodeling.
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INTRODUCTION
The prevalence of neurodegenerative disorders has been rapidly increasing over the past decades.
These untreatable and often lethal conditions including Alzheimer’s disease (AD), Parkinson’s
disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), affect over
100 million people worldwide (Prince et al., 2013; Browne et al., 2014; Baxter et al., 2015).
Despite differences in age of onset and genetic risk factors associated with the disease, common
pathophysiological features can be identified, including synaptic and glial dysfunction, as well as
cognitive impairments. Synapse loss is an early occurring hallmark in many neurodegenerative
disorders, which correlates best with the appearance and progression of cognitive decline
(DeKosky and Scheff, 1990; Terry et al., 1991; Koffie et al., 2011; Spires-Jones and Hyman,
2014). Abnormal glial function is also recognized as an early pathological feature commonly
observed in neurodegenerative disease (Verkhratsky et al., 2014). However, for a long time, the
prevailing neuro-centric view of pathogenesis has led to the underestimation of key roles for
non-neuronal cells in the brain, primarily glia, which were instead considered as mere bystanders
or secondary responders in the pathological process. Only in the last decade, with the advent
of new genetic, molecular and pharmacological tools, have significant steps forward been made
towards our understanding of glial function, revealing a central role for these cells in disease
(Verkhratsky et al., 2014).
From the Greek word ‘‘glue,’’ glia in the central nervous system (CNS) include three major cell
subsets: astrocytes, microglia and oligodendrocytes. While the latter are mainly responsible for the
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formation of myelin and for providing metabolic support to
axons (Baumann and Pham-Dinh, 2001; Simons and Nave,
2015), microglia and astrocytes cover a variety of functions,
ranging from trophic support to refinement and coordination
of neural networks (Reemst et al., 2016; Allen and Lyons,
2018). Microglia are the resident macrophages of the CNS and
constitute about 10%–15% of all the brain cells. Historically,
they have been regarded exclusively as innate immune cells,
considered to be ‘‘activated’’ only during infection or injury.
In the last decade, however, several new physiological roles
for microglia have been described, revealing a much broader
scenario for the multifaceted tasks performed by these cells
(Tremblay et al., 2011; Sierra et al., 2014; Paolicelli and
Ferretti, 2017). Astrocytes are the more abundant glial cell in
the CNS; their processes closely enwrap synapses, and their
role in regulating synaptogenesis, neurotransmitter recycling
and synaptic transmission is well established (Parpura et al.,
1994; Vesce et al., 1999; Panatier et al., 2011; Chever et al.,
2016). In addition, they play key roles in maintaining the
blood–brain barrier, providing trophic and metabolic support
to neurons (Pellerin et al., 2007; Sofroniew and Vinters, 2010).
Since the recent recognition of a role for glia in refining
synaptic connections, intense investigations have been devoted
to elucidate the molecular mechanisms of glia-meditated synapse
elimination, particularly in the context of neurodegeneration.
The majority of neurodegenerative disorders fall into the
category of ‘‘proteinopathies,’’ because of the characteristic
accumulation of toxic protein aggregates (Ross and Poirier,
2004; Soto and Pritzkow, 2018). In such diseases, pathological
proteins often accumulate at the synapse (Koffie et al., 2009,
2012; Henstridge et al., 2018), thus causing synaptic dysfunction
and likely rendering the synapses vulnerable and primed for
removal (Walsh et al., 2002; Geracitano et al., 2003; Pieri
et al., 2003; Shankar et al., 2007; Crimins et al., 2012).
In the case of AD, for instance, amyloid β (Aβ) peptide
accumulates at the synaptic site long before its extracellular
aggregation in plaques, and it is associated with alterations
in synaptic structures, both in mouse and in human studies
(Gylys et al., 2004; Almeida et al., 2005; Sokolow et al., 2012;
Takahashi et al., 2013).
Synapse elimination could occur via autonomous pathways
within the damaged neuron, due to localized caspases or necrotic
signals (Wishart et al., 2006; Ertürk et al., 2014) or via active
non-cell-autonomous removal of synapses by surrounding glial
cells (Hong et al., 2016; Vasek et al., 2016; Paolicelli et al., 2017).
Evidence for either scenario or even a combination of both
exists. In this review article, we will primarily focus on glial-
dependent synapse loss and revise the recent literature providing
evidence for glial contribution to excitatory-inhibitory network
dysfunction in pathological states.
SYNAPSE REMODELING IN
DEVELOPMENT AND DISEASE
The term synapse, from the Greek συυα´ψις, meaning
‘‘conjunction,’’ refers to the physical point of contact between
two neurons, and thus defines the anatomical site of information
exchange between an axonal input and the recipient dendritic
spine (Harris andWeinberg, 2012). Synapses are highly dynamic
sub-cellular structures, as they can be rapidly formed or
eliminated during plasticity-mediated processes (Engert and
Bonhoeffer, 1999; Matsuzaki et al., 2001). They represent the
structural basis of long-term potentiation (LTP), essential for
memory formation (Matsuzaki et al., 2004). Evidence of the
highly dynamic nature of synapses has been provided by
advances in live imaging techniques, showing that dendritic
spines rapidly appear and disappear as a result of experience-
dependent plasticity upon sensory experience, and learning
processes (Toni et al., 1999; Lendvai et al., 2000; Holtmaat
and Svoboda, 2009; Fu et al., 2012). During early development,
immature neural circuits undergo synaptic refinement, in which
activity-dependent competition between synapses ultimately
results in the elimination of inappropriate connections and
brain plasticity, while strong synapses are reinforced (Penn
et al., 1998; Lichtman and Colman, 2000; Hua and Smith,
2004; Torborg and Feller, 2005; Mikuni et al., 2013; Fields
et al., 2014; Robin et al., 2018). Importantly, the proposed
mechanism of the strongest ‘‘winning inputs’’ (Personius and
Balice-Gordon, 2000) is consistent across a number of models,
namely the neuromuscular junction (NMJ; Wang et al., 2014),
the Purkinje fibers in the cerebellum (Mason and Gregory,
1984; Hashimoto and Kano, 2003; Kakegawa et al., 2015) and
the retino-thalamic system (Hong and Chen, 2011), suggesting
that activity-dependent remodeling of synapses is a conserved
process across the central and peripheral nervous system. In vivo
imaging studies recently showed that monocular deprivation
(MD) increases dendritic spine elimination in the developing
mouse visual cortex, with no effects on synapse formation (Zhou
et al., 2017). Interestingly, binocular deprivation (BD), which
entirely suppresses competition between the two eyes, failed to
induce synapse elimination, and resulted by contrast in enlarged
dendritic spine size (Zhou et al., 2017).
The high dynamic remodeling of synapses not only occurs
during early developmental stages, but also persists across the
entire lifespan (Peretti et al., 2015). Live imaging of cortical
regions largely supports the experience-dependent plasticity of
dendritic spines in the adult mouse brain (Xu et al., 2009; Yang
and Zhou, 2009). In vivo imaging of the hippocampus, a highly
plastic structure, has been made possible only recently, upon
novel methods of cortical tissue resection (Pilz et al., 2016). Such
studies have provided evidence for network plasticity with new
spines formed and eliminated in the CA1 stratum radiatum, with
an impressive-previously underscored- spine turnover of ∼40%
within 4 days (Gu et al., 2014; Pfeiffer et al., 2018).
While synapse elimination in the context of brain
development and experience-dependent plasticity is a
physiological process (Wolff and Missler, 1993; Kamiyama
et al., 2006), its later and dysregulated occurrence is recognized
as an early pathological feature of neurodegenerative diseases
(DeKosky and Scheff, 1990; Henstridge et al., 2018). Indeed,
one of the earliest hallmarks of neurodegeneration is the
loss of presynaptic terminals and dendritic spines, which
represents the major correlate of cognitive impairment
(Terry et al., 1991; Scheff et al., 2006, 2014). Structural and
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functional alterations of synapses, culminating in synapse
loss, are associated with sensory, motor, and cognitive
impairments observed in a variety of neurodegenerative
disorders, ranging from AD to motor neuron diseases (MND),
and often precede clinical manifestations (Selkoe, 2002;
Henstridge et al., 2018). Yet, the causes and the molecular
mechanisms leading to pathological synapse loss have not
been fully elucidated (Henstridge et al., 2016). On one hand,
the regenerative capacity of synapses seems to be significantly
reduced in the disease state, as shown in prion-infected and
AD mouse models (Peretti et al., 2015); on the other hand,
aberrant synaptic pruning or lack of trophic support by
surrounding glia cells can contribute to the drastic reduction in
synapse number.
CONTRIBUTION OF GLIA TO SYNAPSE
ELIMINATION
Recent literature highlights glial cells as active participants in
the process of neural circuits refinement (Figure 1). Microglia
and astrocytes contribute to accurate network formation by
directly pruning redundant synapses during early development,
and thus shaping brain connectivity (Paolicelli et al., 2011;
Chung et al., 2013; Hakim et al., 2014; Zhan et al., 2014;
Risher et al., 2014; Filipello et al., 2018). In addition,
glia can also act indirectly to induce effects on synaptic
function, via the release of soluble modulators (Chung et al.,
2015). Compelling evidence shows that synapse elimination
by glia is important in the activity-dependent wiring of
FIGURE 1 | Glial control of synaptic homoeostasis. Synapses exists as tri- or even quad-partite structures with glial processes in direct contact with neuronal
components. Glia play important roles in regulating efficient neurotransmitter release and clearance, as well as providing trophic factors to ensure healthy function.
Furthermore, during development glia prune away excess synapses and by doing so, fine-tune the excitatory/inhibitory balance within developing neuronal networks.
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the brain, with microglia and astrocytes selectively removing
the weaker synapses upon input competition (Schafer et al.,
2012; Chung et al., 2013; Sipe et al., 2016; Yang et al.,
2016). For example, the visual system is a well-characterized
model for experience-dependent synaptic refinement (Wiesel
and Hubel, 1963), and thus, the developing retino-thalamic
system has been frequently used for studying competition of
synaptic inputs, which project from the retinal ganglion cells
(RGCs) to the relay neurons in the dorsal later geniculate
nucleus (dLGN), and then to the primary visual cortex.
This model has been influential in revealing that microglia
are active players in experience-dependent remodeling of
neural circuits (Tremblay et al., 2010; Schafer et al., 2012;
Sipe et al., 2016). Sensory deprivation, by closure of one
eye, during the visual critical period results in enhanced
engulfment of synaptic terminals by microglia and astrocytes
(Chung et al., 2013; Sipe et al., 2016), whereas BD, achieved
by pharmacological blockade, drastically reduces astrocyte-
mediated synaptic pruning, further confirming that active
competition of synaptic inputs is required for glial-dependent
synapse remodeling (Chung et al., 2013). Several pathways
have been implicated in this process, including fractalkine
signaling (Cx3cr1/Cx3cl1), DAP12/triggering receptor expressed
on myeloid cells 2 (TREM2) signaling and the complement
pathway for synapse elimination by microglia (Paolicelli et al.,
2011; Schafer et al., 2012; Filipello et al., 2018), and MEGF10 and
MERTK for astrocyte-mediated synapse engulfment (Chung
et al., 2013). Dysfunctional regulation of such pathways or
intrinsic defects in glia are possible causes for the pathological
synaptic pruning observed in neurodegeneration. Indeed, a
growing body of evidence indicates that glia-mediated synapse
removal becomes dysregulated in aging and disease. A prominent
hypothesis is that an increased activation of the complement
cascade, associated with neurodegenerative disorders, enhances
complement deposition on synaptic terminals, priming the
synapses for removal and thus mediating aberrant synapse
elimination. In support of this, distinct animal models of
neurodegeneration (discussed below) exhibit upregulated levels
of complement C3 and C1q, and subsequent synapse loss
(Fonseca et al., 2004; Michailidou et al., 2015, 2017; Shi
et al., 2015, 2017; Lui et al., 2016). Also, injection of Aβ
peptide in wild-type mice was shown to increase the levels
of complement molecules, and in turn to promote synapse
engulfment by microglia (Hong et al., 2016). A consistent role
for complement in opsonizing synapses for removal has been
shown in ageing models, with complement C3-deficient mice
protected from age-related hippocampal decline (Shi et al.,
2015). Complement upregulation was also reported upon viral
infection. However, while such increase is critical for mediating
microglial removal of presynaptic terminals in the hippocampus
of West Nile Virus (WNV) infected mice (Vasek et al., 2016),
it appears dispensable in IFN-γ mediated microglial synaptic
stripping upon lymphocytic choriomeningitis viral infection (Di
Liberto et al., 2018). Type I IFN signaling instead mediates
synapse elimination by microglia in a mouse model of systemic
lupus erythematosous (SLE), an incurable autoimmune disease
(Bialas et al., 2017).
Purinergic signaling also plays crucial roles in microglia-
mediated synapse refinement. ATP is a major signalingmolecule,
that acts as a danger signal once released extracellularly
and profoundly affects microglial function (George et al.,
2015; Rodrigues et al., 2015). Microglial processes are rapidly
directed towards sources of ATP through the activation of
P2Y12 receptors (Davalos et al., 2005). Activity-dependent
synapse remodeling in the developing mouse visual cortex
has been shown to strongly rely on such purinergic pathways
in microglia, as knockout mice exhibited defective ocular
dominance plasticity (Sipe et al., 2016). In addition, calcium-
mediated purinergic receptors regulate microglial phagocytoses
during postnatal brain development (Sunkaria et al., 2016).
Microglia not only sense and respond to ATP, but they
can also serve as a source of purines, which modulate synaptic
plasticity, thus representing an alternative mechanism for
microglia-induced synaptic refinement (George et al., 2016).
Also, intrinsic glia dysfunction caused by genetic mutations
can lead to aberrant synapse elimination. Loss of progranulin
was shown to promote synaptic pruning by microglia,
in a C1q-dependent manner (Lui et al., 2016). We have
reported evidence for enhanced synapse engulfment, in
the motor/somatosensory cortex of mice selectively lacking
microglial TDP-43 (Paolicelli et al., 2017).
Other immune-related molecules such as CD47, have been
recently described to work as ‘‘spare me’’ signals, and to
protect synapses from excessive microglia-mediated pruning
(Lehrman et al., 2018).
An interesting aspect that warrants further investigation is the
cross-talk between microglia and astrocytes. Collecting evidence
indicates that microglia can modulate astrocytic function,
and conversely astrocytes can regulate microglial phenotypes
(Jha et al., 2018). Microglial derived ATP, for instance, acts
through the astrocytic receptor P2Y1, thus modulating excitatory
neurotransmission and providing neuroprotection (Pascual
et al., 2012; Shinozaki et al., 2014). Microglia can also induce
neurotoxic astrocytes through the release of C1q, tumor necrosis
factor-α (TNF-α), and interleukin-1α (IL-1α) (Liddelow et al.,
2017). Recent findings show that astrocytic NF-kB activation
induce a Wnt-dependent microglial proliferation, identifying
astrocytes as important regulator of microglial expansion (Ouali
Alami et al., 2018). Astrocyte-mediated synapse elimination
has been shown to occur soon after acute sleep deprivation,
before microglia-mediated remodeling, which is engaged only
subsequently, if sleep deprivation is prolonged for several hours
(Bellesi et al., 2017). It is thus tempting to speculate that
astrocytes and microglia can act together in coordination, to
ensure efficient synapse remodeling. Fine-tuned communication
between microglia and astrocytes is crucial for proper brain
functioning. Thus, a better understanding of the cellular
processes involved in this cross-talk will be essential to elucidate
the role of glia in the diseased brain.
Lifestyle factors related to dementia, such as nutrition,
sleep quality and stress, are heavily implicated in glia-mediated
synapse loss and cognitive decline (Cope et al., 2018; Rajendran
and Paolicelli, 2018). On the other hand, large-scale human
genetic studies have identified glia-specific genes as genetic
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risk factor in a range of neurological conditions from autism
(Voineagu et al., 2011) to AD (Karch and Goate, 2015;
Gosselin et al., 2017). Taken together, all this evidence reveals
glia as a common link between many of the world’s most
impenetrable diseases.
IMBALANCE BETWEEN EXCITATION AND
INHIBITION IN PATHOLOGICAL STATES
The balance between the excitatory and inhibitory control
of synaptic activity needs to be tightly maintained to ensure
proper functioning and plasticity of neural circuits (Hensch
and Fagiolini, 2005; Harauzov et al., 2010). Pre-synaptic
terminals of excitatory synapses release glutamate as their major
neurotransmitter, and are thus defined glutamatergic. Glutamate
is received at the post-synapse by the ionotropic [N-methyl-
D-aspartate receptors (NMDARs) and 2-amino-3-3-hydroxy-5-
methyl-isoxazol-4-yl propanoic acid receptors (AMPARs)] and
metabotropic (mGluR) glutamate receptors. On the other hand,
pre-synaptic terminals at inhibitory synapses primarily release γ-
aminobutyric acid (GABA), and are thus defined GABAergic.
GABA is post-synaptically received by ionotropic (GABAAR)
and metabotropic (GABABR) GABA receptors. In terms of
spatial organization, glutamatergic synapses are located almost
exclusively on dendritic spines, whereas GABAergic synapses
can be spread along the dendritic shaft, somata, and axon initial
segments (Fritschy and Brünig, 2003; Penzes et al., 2011).
Excitatory neurons increase or decrease the accumulation
of glutamate receptors at synaptic sites in response to changes
in their own firing rates, through what has been defined as
homeostatic synaptic scaling (Turrigiano et al., 1998; Turrigiano
and Nelson, 2004; Turrigiano, 2008). The aim is to stabilize
neuronal firing by adjusting its own synaptic strength to
compensate for perturbations in surrounding neural activity
(Ibata et al., 2008).
Network synchrony and oscillatory brain rhythms are
promoted and controlled by the activity of inhibitory GABAergic
interneurons across the entire lifespan, with important cross-
talks with astrocytes modulating synaptic efficacy (Buzsáki et al.,
2004; Klausberger and Somogyi, 2008; Perea et al., 2016; Sardinha
et al., 2017; Mederos et al., 2018). Indeed, in the early stages of
several brain disorders, impairment in inhibitory transmission
combined with possible defects in homeostatic synaptic scaling at
excitatory synapses might drastically compromise the excitation/
inhibition (E/I) balance (Palop and Mucke, 2016). Defective
inhibition or aberrant excitation in brain development has been
associated with severe alteration in the E/I ratio (observed in
ASD for example) and considered to be causally linked to
behavioral abnormalities (Rubenstein and Merzenich, 2003; Gao
and Penzes, 2015; Nelson and Valakh, 2015). In support of
this, modulation of prefrontal cortex E/I by optogenetics has
recently been shown to rescue deficits in social behavior, in a
mouse model of autism (Selimbeyoglu et al., 2017). Nevertheless,
in other cases with memory alterations, selective changes of
glutamatergic synaptic markers, have been reported without
evident changes of GABAergic synaptic markers, in models of
childhood epilepsy, diabetic encephalopathy and repeated stress,
supporting the complexity of this topic (Cognato et al., 2010;
Duarte et al., 2012; Canas et al., 2014; Kaster et al., 2015).
In neurodegeneration, such as in AD, network activities
are altered even decades before clinical disease onset and are
associated with diverse cognitive manifestations (Palop and
Mucke, 2016). To date, the mechanisms and pathophysiological
consequences of these alterations, which include activation and
deactivation deficits of neural circuits, are poorly understood.
Importantly, recent findings suggest that network activities
can be experimentally or behaviorally manipulated to improve
cognitive function in AD mouse models (Sanchez et al., 2012;
Busche et al., 2015), and even in patients at risk of AD
(Bakker et al., 2012, 2015). Overall, impairments in inhibitory
connections, with consequent hyperexcitation, are emerging
as potential mechanisms underlying cognitive dysfunction
in several neurodegenerative diseases. On the other hand,
selective increase in inhibition, via pharmacogenetic activation
of parvalbumin interneurons, was recently shown to have
beneficial effects, preventing stress-induced synapse loss in vivo
(Chen et al., 2018).
Considering the complexity of our brain, it is easy to
imagine that the fine-tuned balance between excitation and
inhibition is not simply the net output of neuronal firing, but
is rather the result of a highly regulated cross-talk amongst
numerous cell types that are able to sense synaptic activity
and to assist neurons to dynamically and appropriately adjust
synapse strength and number. In this scenario, glial cells, such
as astrocytes and microglia, which are known to closely interact
with neural networks, can directly contribute to homeostatic
synaptic scaling. Indeed, it has been proposed that glia participate
directly in the homeostatic, activity-dependent regulation of
synaptic connectivity through the release of TNF-α, a cytokine
known to increase the cell surface expression of AMPA
receptors (Stellwagen and Malenka, 2006). Similarly, several
other molecules released by microglia and astrocytes might exert
a direct regulation of plasticity by affecting receptor composition
at the synapse, such as BDNF and IL1β (Parkhurst et al., 2013;
Rizzo et al., 2018).
In addition to mechanisms mediated by release of soluble
factors, it would be important to investigate whether refinement
of synaptic connections by glial synaptic pruning also occurs
to reinforce synaptic scaling. Growing evidence indicates that
microglia are capable of sensing synaptic activity and act
as key players in homeostatic regulation of neural firing
(Li et al., 2012; Béchade et al., 2013; Ji et al., 2013).
Lipopolysaccharide (LPS) injection in mice promotes transient
but selective microglia-mediated removal of inhibitory synapses,
which ultimately results in neuroprotection by suppressing
inhibition and increasing synchronic neural firing (Chen et al.,
2014). LPS-driven inflammation has profound effects on synaptic
transmission (Pickering and O’Connor, 2007). Recent studies
show that short-term LPS stimulation of microglia in spinal
cord specifically decreases inhibitory glycinergic post-synaptic
currents (Cantaut-Belarif et al., 2017). It is thus plausible to
speculate that loss of excitatory synapses could be counteracted
by microglia through removal of inhibitory inputs. On the
other hand, astrocytes are much less motile, but their processes
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are more stably associated with synapses, and even considered
a constant synaptic element, forming the so-called ‘‘tripartite
synapse’’ (Araque et al., 1999). Interestingly, perturbations in
astrocytic function lead to selective reduction in inhibitory,
but not excitatory currents, as a consequence of rapid
GABA depletion induced by downregulation of the glutamine
synthetase enzyme (Ortinski et al., 2010).
Astrocytes also play critical roles in activity-dependent
synapse elimination, as previously discussed. In the light of
such observations, glia cells represent the perfect candidates
for monitoring and eventually restoring E/I networks balance,
through selective remodeling of excitatory or inhibitory inputs.
Overall, a dysregulated ratio between excitation and
inhibition has significant implications in behavioral outputs
associated with neurodevelopmental and neurodegenerative
disorders, however the exact molecular and cellular processes
at the origin of such dysfunction are yet to be elucidated. In
the following paragraphs we will review the recent literature,
highlighting possible links between glia-mediated synaptic
remodeling and dysregulation of the E/I network balance
in neurodegeneration.
ALZHEIMER’S DISEASE
AD is the most common cause of dementia in the elderly, and
despite its increasing prevalence there are no effective treatments
available. The rare familial form of AD involves mutations
of the amyloid precursor protein gene (APP) and Presenilins
1 and 2 (PSEN1 and PSEN2), which cleave APP to form Aβ
species (Hardy and Higgins, 1992; Chávez-Gutiérrez et al., 2012).
Late-onset (LOAD), or sporadic AD accounts for more than 95%
of the Alzheimer’s cases, but has no clear etiology. With ageing
being the strongest risk factor, several genetic polymorphisms
in various gene loci have been associated with increased AD
risk, such the Apolipoprotein E4 (ApoE4) allele or the R47H
mutation in Trem2 (Roses, 1996; Guerreiro et al., 2013; Jonsson
et al., 2013). AD is characterized by deposition of extracellular
Aβ plaques, intracellular neurofibrillary tau tangles (NFTs),
and progressive neurodegeneration accompanied by cognitive
decline (Spires-Jones and Hyman, 2014). Several studies have
focused on the pathological role of Aβ oligomeric species
as a major player in neuronal and network dysfunction at
early stages of the disease progression, thus providing a broad
range of causative mechanisms (Cleary et al., 2005; Shankar
et al., 2008; Li et al., 2011). For instance, Aβ can cause
E/I imbalance through disruption of fast-spiking GABAergic
inputs (Ren et al., 2018). Mutations in the APP leading
to increase in Aβ oligomerization (E693 Osaka mutation;
Tomiyama et al., 2010) have also been shown to cause selective
GABAergic depletion in recessive familial AD (Umeda et al.,
2017). Many of the LOAD risk genes, including APOE and
TREM2, involve the brain’s immune system and the majority
of them are highly enriched in microglia (Gosselin et al.,
2017), suggesting glial cells are causally implicated in the
pathogenesis of AD, and thus might be important players
in the E/I imbalance observed already in the early stages
(Henstridge et al., 2019).
The microglial and astrocyte reactivity in AD and their
physiological role in synaptic pruning has inspired a new wave
of research into glial-mediated synapse loss in AD as a driver of
network dysfunction (Serrano-Pozo et al., 2013; Rodriguez et al.,
2014). Figure 2 summarizes the role of glia in mediating synaptic
refinement in AD.
Other immune cells, such as lymphocytes and neutrophils
may play important roles in the onset and progression of AD,
also interacting with resident glia cells (Town et al., 2005; Xie and
Yang, 2015; Ferretti et al., 2016).
Microglia and Astrocytes in Synapse Loss
in AD
It is well established that excitatory synapses are vulnerable
in AD. Specifically, oligomeric Aβ (oAβ) not only induces
synaptotoxicity but also synaptic weakening through prolonged
long-term depression (LTD) and impaired LTP (Shankar et al.,
2008; Li et al., 2009; Wu et al., 2010). In turn, glutamatergic
signaling deficits in AD can range from NMDA and AMPAR
internalization causing synaptic weakening (Zhang et al., 2003;
Snyder et al., 2005) to NMDA-mediated glutamate excitotoxicity
(Esposito et al., 2013). Recent reports suggest that other
mechanisms of synapse dysfunction, such as the upregulation
of adenosine A2A receptor might even occur before and
independent of defective glutamate receptors, in a mouse model
of AD (Viana da Silva et al., 2016).
Most studies demonstrating synapse loss by microglia have
focused on the engulfment of pre- and post-synaptic markers,
by co-localization approaches, with a preferential focus on
excitatory synapses. The role of complement, in virtue of
its role in mediating synaptic pruning during development,
has been extensively investigated in the context of synapse
elimination in AD. Indeed, in two amyloidopathy models
of AD (Tg2576 and APP/PS1) crossed with C1q knockout
mice, lack of C1q protected against synaptophysin loss in the
hippocampus of aged mice (Fonseca et al., 2004). Similarly,
more recent work has shown increased co-localization of C1q
with excitatory post-synaptic densities-95 (PSD-95) in the J20
APP-overexpressing mouse model, as well as in transgenic
APPsw/PSEN1DE9 mice, and also following injections of
oAβ (Hong et al., 2016; Bie et al., 2019). Synaptotoxicity
and LTP impairments induced by oAβ were also prevented
in C1q knockout mice or upon administration of C1q
neutralizing antibodies, suggesting C1q is critical for synaptic
elimination (Hong et al., 2016; Bie et al., 2019). A proposed
mechanism for C1q upregulation in hippocampal synapses
is via metabotropic glutamate receptor signaling (mGluR1;
Bie et al., 2019), which has been shown to be involved in
synaptic LTD upon amyloid challenge (Chen et al., 2013).
Overall, upregulation in complement molecules is associated
with higher internalization of synaptic markers by microglia and
with overall synaptic loss. In agreement with these outcomes,
APP/PS1 mice lacking C3 showed a milder pro-inflammatory
biochemical and morphological profile, reduced Aβ-associated
microgliosis and astrogliosis, and greater levels of pre-synaptic
(synaptophysin, VGLUT1) and excitatory post-synaptic (homer,
PSD-95) markers compared to APP/PS1 mice expressing
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FIGURE 2 | Pathophysiology of Alzheimer’s disease (AD). The build-up of pathological amyloid and tau species leads to neurodegeneration via numerous
autonomous and non-autonomous pathways. Glial cells release pro-inflammatory mediators and lose their ability to regulate glutamate homeostasis, leading to
synaptic dysfunction. Furthermore, the synaptic accumulation of proteins from the complement system leads to glial-dependent synapse engulfment and loss.
C3 normally (Shi et al., 2017). Importantly, C3 absence in 16-
month-old APP/PS1 mice, spared cognitive deficits as shown
by enhanced spatial memory. This suggests that in AD,
healthy synapses that would not normally require physiological
elimination may be aberrantly targeted by the complement
system for elimination, partly eliciting the cognitive decline
seen in AD.
Secretion of pro-inflammatory mediators by microglia is
likely to occur concomitantly to phagocytosis, contributing to
the AD-related synapse loss. Prolonged exposure to TNF-α in
a triple transgenic AD-like model (3xTg) induced neuronal
loss, microgliosis and upregulated C3 as well as intracellular
Aβ levels (Janelsins et al., 2008). In the TgCRND8 AD mouse
model, C3 was also upregulated in response to another potent
pro-inflammatory cytokine, IFN-γ (Chakrabarty et al., 2010).
Additionally, in culture assays, microglial IL-6 and nitric oxide
(NO) have direct synaptotoxic effects on neurons (Azevedo et al.,
2013). Therefore, microglia not only can directly mediate synapse
elimination, but can also prime synapses for removal through
released soluble factors.
The presence of the allele E4 for APOE (a major cholesterol
carrier) is the strongest genetic risk factor influencing
susceptibility to LOAD and it is associated with increased
synapse loss (Koffie et al., 2009, 2012; Liu et al., 2013; Tzioras
et al., 2018) as well as complement activation (McGeer et al.,
1997). Transcriptomic studies have heavily implicated microglial
APOE as a common facilitator of many AD-associated
conditions, including amyloidosis, tauopathy, ageing and
inflammation (Kang et al., 2018; Lin et al., 2018; Ulrich et al.,
2018). Specifically, microglia close to Aβ plaques develop a
disease associated phenotype and upregulate Apoe expression
in a TREM2 dependent pathway (Keren-Shaul et al., 2017;
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Krasemann et al., 2017). APOE4 expressing mice also exhibit
increased hippocampal gliosis and decreased levels of both
synaptophysin and excitatory postsynaptic proteins (Zhu et al.,
2012). Crossing APOE4 mice to the 5xFAD AD-like mouse
model resulted in exacerbated Aβ-associated gliosis, presence of
dystrophic neurites and IL-1β neuroinflammation (Rodriguez
et al., 2014). Moreover, in human post mortem brains, theAPOE4
genotype is associated with an increase in microglial markers of
activation including CD68, MSR-A and CD64 and decrease in
homeostatic Iba1 (Minett et al., 2016). It is, therefore, compelling
to hypothesize that, in carriers of the APOE4 allele, microglia
might be more prone to mediate pathological synapse loss.
Astrocytes and their many functions have been extensively
studied in the context of AD (González-Reyes et al., 2017;
Liddelow and Barres, 2017; Perez-Nievas and Serrano-Pozo,
2018), albeit their role in synapse loss is less clear. Both
human and mouse studies have reported upregulation of reactive
astrocyte signatures (GFAP) in the presence of an APOE4
allele (Overmyer et al., 1999; Ophir et al., 2003; Belinson
and Michaelson, 2009; Shi et al., 2017). In a recent study,
induced pluripotent stem cells from APOE4 AD patients were
differentiated into astrocytes and were then genetically modified
using CRISPR-Cas9 to generate an APOE3 genotype (Lin et al.,
2018). This approach revealed that APOE4 to APOE3 conversion
is sufficient to rescue the impaired phagocytic ability of astrocytes
towards Aβ (Lin et al., 2018). Interestingly, and unexpectedly,
an allele-dependent role for APOE was also shown in respect
to mediating synapse elimination, with APOE2 enhancing and
APOE4 decreasing the rate of synaptic pruning by astrocytes
(Chung et al., 2016). This apparent controversy might be
explained if we assume that homeostatic elimination of damaged
synapses occurs constantly in the healthy brain. Thus, one
could speculate that ApoE4 carrier would be impaired in such
glia-mediated ‘‘homeostatic synapse remodeling.’’
Only recently there was evidence of reactive astrocytes
engulfing synapses in AD, with electron microscopy showing
dystrophic VGLUT1-positive terminals being cleared by
astrocytic endfeet in the hippocampus of APP/PS1 mice and
in late stages of AD (Gomez-Arboledas et al., 2018). Whether
this clearing mechanism is exacerbated in AD and contributes
to excessive synaptic elimination is still under debate. The
decreased phagocytic ability of reactive and APOE4-expressing
astrocytes in development introduces new questions as to how
these cells change in the context of AD and thus contribute
to neurodegeneration.
Glia Implications in E/I Imbalance in AD
Mounting evidence from mouse model studies suggest that,
in the amyloid-depositing brain, functional impairments of
local neuronal circuits lead to disruption in the E/I balance,
which then result in large-scale networks defects (Busche et al.,
2008; Busche and Konnerth, 2016; Palop and Mucke, 2016).
Loss of inhibitory interneurons results in impaired oscillatory
rhythm (Ramos et al., 2006; Baglietto-Vargas et al., 2010; Verret
et al., 2012) leading to epileptiform activity (Vossel et al.,
2016) and network hyperexcitability (Brown et al., 2018) in a
subset of AD patients. Some studies have reported reduction of
inhibitory pre-synaptic VGAT and GAT1 peri-somatic terminals
on pyramidal neurons close to plaques, both in AD post mortem
cases and aged APP/PS1 mice (Garcia-Marin et al., 2009). Others
have found no such loss of inhibitory synapses in neither the
same APP/PS1 model nor AD cases at comparable pathological
stages; conversely, excitatory VGLUT1 boutons were found to
be significantly reduced (Mitew et al., 2013; Canas et al., 2014).
In the same study, Aβ was also suggested to increase astrocyte
GABA synthesis, highlighting a possible implication of astrocytes
as a source of E/I imbalance in AD (Mitew et al., 2013).
Microglia, too, may play an active role in compromising the
equilibrium of excitatory vs. inhibitory synaptic transmission in
AD, by promoting loss of selective synapses (i.e., glutamatergic
vs. GABAergic). Evidence for microglia engulfing excitatory
inputs in AD mouse models have been provided (Hong
et al., 2016; Paolicelli et al., 2017), however, evidence for the
engulfment of inhibitory connections is still lacking. Whether
microglia can directly contribute to E/I imbalance in AD is
currently under debate, and further studies are required to
investigate this possibility. A clear implication of microglia in
the AD brain has been recently underscored by the use of PET
tracers in vivo, which are capable of specifically revealing the
microglial component of neuroinflammation (Edison et al., 2018;
Horti et al., 2019).
PARKINSON’S DISEASE
PD is a neurodegenerative disorder characterized by massive
degeneration of nigro-striatal dopaminergic neurons, which
leads to progressive motor and cognitive symptoms. It is
the second most common neurodegenerative disease and
affects 2%–3% of the population over the age of 65 years
(Poewe et al., 2017). The general term ‘‘parkinsonism’’ refers to
the ensemble of movement disorders defined by the appearance
of bradykinesia, rigidity or tremor. Cognitive impairment, in
addition, is an important non-motor symptom of PD, with a
mean duration from clinical disease onset to dementia of about
10 years (Aarsland et al., 2011; Selnes et al., 2017). A key
neuropathological hallmark of the PD brain is the abnormal
deposition of intraneuronal (Lewy bodies) and intraneuritic
(Lewy neurites) fibrillary aggregates, mainly composed of
α-synuclein (α-syn) and referred to as Lewy pathology. α-syn
inclusions, initially thought to be limited to the substantia nigra
pars compacta of the striatum, have been associated with the
primary cause of neuronal loss in PD (Desplats et al., 2009).
However, post mortem brain examinations of patients affected
by PD revealed that Lewy pathology is not only confined to
the striatum, but also affects other well-defined brain regions,
possibly following a progressive spreading pattern (Del Tredici
et al., 2002; Beach et al., 2009; Colom-Cadena et al., 2017). Staging
of Lewy pathology in PDwas first proposed by Braak et al. (2003),
based on histological examinations showing the anatomical
caudo-rostral progression of disease over time. Accumulating
in vitro and in vivo evidence indicates that α-syn can undergo
toxic conformational changes, spread from cell to cell, and
initiate the formation of pathological aggregates, in a prion-like
manner (Kordower et al., 2008; Li et al., 2008; Luk et al., 2012;
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Masuda-Suzukake et al., 2013). Together with the progressive
stages of the disease, these data are in support of the spreading
hypothesis, according to which Lewy pathology arises in specific
brain nuclei and spreads to other structures through synaptic
connections (Recasens and Dehay, 2014).
Transgenic animal models with α-syn overexpression exhibit
neuronal dysfunction in the absence of cell loss, indicating that
disruptions of synaptic transmission occur as an initial event,
preceding α-syn-induced neuronal cell death (Janezic et al., 2013;
Phan et al., 2017). Experimental evidence in fact shows that
synaptic dysfunction is caused by presynaptic accumulation of
α-syn aggregates, which impair axonal transport by affecting key
proteins governing synaptic vesicle release (Kramer and Schulz-
Schaeffer, 2007; Bellucci et al., 2012; Anichtchik et al., 2013).
Early synaptic dysfunction in PD has been supported by
genetic evidence, with recently identified mutations in genes
involved in clathrin-dependent synaptic vesicle endocytosis
(SVE), such as DNAJC6 (auxilin) and SYNJ-1 (synaptojanin 1),
in patients with juvenile and early-onset atypical parkinsonism
(Nguyen and Krainc, 2018). In these models, a central
role for glia cell have been also proposed, although
causative mechanisms still await further supportive evidence
(Teismann et al., 2003).
Microglia and Astrocyte-Mediated
Synapse Impairment in PD
Synapse loss in PD correlates with the pathological deposition
of α-syn at the pre-synaptic site. Indeed, prolonged exposure
to α-syn oligomers in hippocampal slices was shown to
regulate synaptic transmission and impair LTP by activating
NMDARs (Diógenes et al., 2012). Most of the studies aimed
at elucidating the cellular basis of PD, have focused so far
on mechanisms of neuronal dysfunction; however, PD-related
genes are also expressed in astrocytes and microglia. Thus,
it is likely that dysregulation of such genes may contribute
to disease onset and progression via glia-mediated processes.
Astrocytic roles in glucose metabolism are well described, and
mutations in Parkin, PINK1, DJ-1 and LRKK2, associated
with PD, have been shown to affect astrocytes function
(Choi et al., 2013).
Parkin is a ubiquitin ligase largely implicated in PD,
however its role in modulating glial specific function has just
started to be unraveled. Recent studies show that parkin loss
exacerbates inflammation and promotes survival of activated
microglia by inhibiting necroptosis, thus contributing to
chronic neuroinflammation (Dionísio et al., 2018), whereas in
astrocytes it induces endoplasmic reticulum stress. Whether
such effects can negatively impact on synaptic function and
mediate synapse loss, however, remains to be elucidated.
Similarly, novel evidence for DJ-1 modulation of glial
function are emerging. DJ-1, encoded by PARK7 gene, is a
ubiquitously-expressed multifunctional protein which regulates
anti-oxidant and anti-apoptotic gene expression (Canet-
Avilés et al., 2004). DJ-1 knockdown in astrocytes was shown
to impair astrocyte-mediated neuroprotection in primary
neurons (Mullett and Hinkle, 2009; Kim et al., 2016), whereas
astrocytic over-expression of DJ-1 prevented oxidative stress
and mitochondrial dysfunction, leading to enhanced neuronal
survival in vitro and in vivo (De Miranda et al., 2018; Frøyset
et al., 2018). On the other hand, DJ-1 has been also shown to
modulate microglial function, with its deficiency impairing
autophagy, reducing α-syn phagocytosis and inducing a
constitutive pro-inflammatory activation (Meiser et al., 2016;
Nash et al., 2017). Mutations in LRKK2, another multifunctional
protein associated with late-onset familial PD, has been shown
to affect basic glial function. For instance, pathogenic mutations
impair lysosomal function in astrocytes (Henry et al., 2015), and
attenuate motility in microglia, preventing efficient response
to brain damage (Choi et al., 2015). Altogether, these findings
support the implication of glial dysfunction in the synaptic
impairment occurring in PD.
Glial Contribution to E/I Imbalance in PD
The pathophysiology of PD is characterized, among other
features, by a prominent imbalance within striatal activity.
Dopamine (DA) has excitatory effects on the projections from
the striatum to the internal segment of globus pallidus (GP),
defined as the direct pathway, acting through D1 receptors
(D1Rs). The same neurotransmitter, however, exerts inhibitory
effects on the projection from the striatum to the external
segment of GP through D2Rs, or indirect pathway (Surmeier
et al., 2007). Loss of DA, therefore, has complex consequences
on multiple levels. Several studies in rodents, using both
pathogenic 6-hydroxydopamine (6-OHDA) and 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) models, have shown
that the progressive loss of striatal DA leads to a significant loss
of glutamatergic synapses on medium spiny neurons (MSNs)
of the dorsal striatum (Ingham et al., 1989; Zaja-Milatovic
et al., 2005; Day et al., 2006), and that dendritic spines are
decreased and enlarged specifically in the direct pathway neurons
(Nishijima et al., 2014). Overall, the loss of dopaminergic
input from the substantia nigra alters the equilibrium between
excitatory and inhibitory control from the basal ganglia to the
motor cortex.
Recent studies have highlighted the existence of
subpopulations of astrocytes, with circuit-specific roles in
the basal ganglia (Martín et al., 2015). Considering that both the
direct and indirect pathways are fundamental for motor control,
and are associated with motor deficits in PD and Huntington’s
diseases, the selective regulation of specific synapses by astrocytes
may be involved in the coordinated activity of these networks in
the striatal function, therefore, pointing to astrocytes as central
players in these disorders (Martín et al., 2015).
However, whether and how glia cells contribute to the E/I
imbalance in PD remains elusive.
It has recently been proposed that microglia may compensate
for dopaminergic neuron loss through selective elimination of
glutamatergic synapses from the subthalamic nucleus (Aono
et al., 2017). By using the 6-OHDA-induced experimental
Parkinsonism rat model, the authors showed a specific increase
of activated microglia in the substantia nigra pars reticulata
(SNr), engulfing excitatory pre- and post-synaptic elements.
These findings suggest that microglia may be involved in a
negative feedback in the indirect pathway of the basal ganglia
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to compensate for the loss of dopaminergic neurons in PD
pathology (Aono et al., 2017). A central role for astrocytes
has also been proposed in the PD brain, based on the
observation that loss of DA neurons in the substantia nigra
is associated with increased density of activated astrocytes
(Hirsch et al., 2006; Gomide and Chadi, 2005; McGeer and
McGeer, 2008). Only recently, however, it has been shown
that striatal astrocytes engulf dopaminergic debris in the
6-OHDA model (Morales et al., 2017). Interestingly, α-syn was
observed within astrocytic processes already 4 h after 6-OHDA
administration, whereas the amyloid precursor protein (APP),
found at synapses and accumulated in bulb-like structures of
degenerating axons, was never found inside astrocytes. These
findings suggest a selective engulfment of synaptic terminals
by astrocytes, rather than a non-specific clearance of cellular
debris (Morales et al., 2017). The contribution of microglia and
astrocytes to synapse loss observed in PD is summarized
in Figure 3.
AMYOTROPHIC LATERAL SCLEROSIS
(ALS)
ALS is caused by the breakdown of upper and lower motor
neurons leading to the progressive weakness and atrophy
of muscle, often resulting in respiratory failure and death
within a few years of diagnosis. It is the most common
form of MND, yet we still do not have a unifying theory of
disease pathogenesis. Most cases (90%) are sporadic, with the
remaining 10% due to known mutations in a growing number
of disease-associated genes, such as c9orf72, SOD1, FUS and
TDP-43 (Renton et al., 2014). Mounting evidence suggests
that disconnection of the neuromuscular synapse occurs very
early in the disease, with an initial toxic insult at the synapse,
leading to disconnection of axons from their target cell, axonal
breakdown and ultimately neuron death. This model led to
the popular ‘‘dying back’’ hypothesis of disease progression
(Frey et al., 2000; Fischer et al., 2004; Pun et al., 2006).
This process has been described at both peripheral synapses
at the NMJ and synapses in the CNS, however the toxic
insult at either site has yet to be identified. An alternative
theory is the ‘‘dying forward’’ hypothesis, which posits that
breakdown of primary motor neurons in the brain leads to
subsequent loss of secondary motor neurons in the periphery,
and thus muscular denervation. Cortical hyperexcitability has
been observed early in ALS brains using a number of imaging
techniques and it is known that chronic hyperexcitability results
in excitotoxicity, leading to motor neuron loss (Bae et al.,
2013). In strong support of hyperexcitability as an important
feature, the most widely prescribed drug for ALS, Riluzole,
acts by dampening excitatory synaptic activity in the brain
(Doble, 1996). Given the complex heterogeneity of ALS, it is
likely that both dying forward and dying back processes occur
in disease, however, regardless the nature of the predominant
process, they ultimately converge on synaptic dysfunction. Cell
autonomous and non-autonomous pathways have been studied
in both pathogenic pathways, with glia strongly implicated in
ALS progression.
Synaptic Alterations in ALS
ALS has historically been considered exclusively a motor neuron
disease, with much of the early research focused on the central
and peripheral components of the motor system. Recent studies,
however, have revealed that ALS is a multi-system disorder,
displaying striking genetic, pathological and clinical overlap with
frontotemporal dementia (FTD; Ling et al., 2013). Approximately
15% of ALS cases receive a co-morbid diagnosis of FTD and
another 30%–40% present with milder cognitive and behavioral
changes, reminiscent of symptoms (Strong et al., 2017). Given
that synapse loss is the strongest correlate with cognitive decline
in AD (Terry et al., 1991), it is interesting to note that synapse
loss also associates with cognitive decline in ALS (Henstridge
et al., 2018), suggesting that synapse loss may be a common
feature of cognitive change in diverse neurodegenerative diseases
(Henstridge et al., 2016).
Betz cells are giant pyramidal neurons located in layer V of
the primary motor cortex where they project mono-synaptically
onto lower motor neurons within the spinal cord. They receive
synaptic input primarily from the premotor cortex, which is
important for the planning and execution of complex movement.
Research has shown that synapses onto anatomically-normal
Betz cells are dysmorphic in the brains of ALS patients (Sasaki
and Iwata, 1999). Furthermore, diverse animal models of ALS
have revealed a common feature of pre-symptomatic loss
of cortical synapses (Qiu et al., 2014; Fogarty et al., 2015,
2016). Lower motor neurons within the spinal cord exhibit
a lower density of axo-somatic synapses in ALS (Sasaki and
Maruyama, 1994a,b), suggesting a disconnection between upper
and lower motor neurons. At the periphery, loss of NMJ synapses
represent one of the first anatomical changes in ALS models,
occurring long before disease symptoms (Frey et al., 2000; Fischer
et al., 2004; Pun et al., 2006). Collectively, these studies show
that synaptic connections throughout the motor system are
vulnerable early in disease.
Microglia-Dependent Loss of Central Synapses
in ALS
Mutations in superoxide dismutase 1 (SOD1), an antioxidizing
enzyme, are associated with ALS.
Animal models overexpressing human mutated SOD1,
display pre-symptomatic changes to cortical motor neurons,
resulting in intrinsic hyperexcitability (Saba et al., 2016) and
an early loss of inhibitory interneurons (Clark et al., 2017).
Thus, it appears in SOD1 animal models of ALS, both
intrinsic hyperexcitability and decreased inhibitory control
play a role in cortical pathophysiology. Recent human studies
using novel neurophysiological techniques have also suggested
that imbalance between intracortical excitatory and inhibitory
systems leads to hyperexcitability (Van den Bos et al., 2018).
Many diverse ALS models exhibit pre-symptomatic synapse
loss. SOD1 models present with early spine loss in the motor
cortex, which worsens with disease progression (Fogarty et al.,
2015; Saba et al., 2016). Mice overexpressing mutated forms
of two RNA-DNA binding proteins commonly associated with
ALS display overt synaptic defects: TDP-43 A315T mice have
progressive loss of spines from P60–P90 compared to wild
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FIGURE 3 | Pathophysiology of Parkinson’s disease (PD). Anatomically, PD is characterized by a loss of striatal dopaminergic neurons. This can lead to disruption of
excitatory and inhibitory circuits, resulting in the clinical motor symptoms. Loss of glutamatergic synapses is apparent in the striatum and aggregates of α-synuclein
(α-syn) are observed in the brains of patients. Furthermore, evidence suggests α-syn accumulates at the synapse, where both astrocytes and microglia have been
shown to engulf α-syn-containing synaptic material.
type mice (Handley et al., 2017) and FUS R521G mice have
a significantly lower density of mature spines in the cortex
at P18 (Sephton et al., 2014). While cell autonomous changes
can influence neuronal morphology, glial cells also have the
ability to significantly influence both excitatory and inhibitory
synaptic systems via the release of toxic mediators or by direct
phagocytosis of neuronal compartments, as described above. The
study of microgliosis in human ALS tissue has mostly been
confined to post mortem studies, which tend to show an increase
in microglia number (Kawamata et al., 1992; Brettschneider
et al., 2012). However, some studies have shown increased
microglial activity in live human ALS brain, using PET imaging
(Turner et al., 2004; Zürcher et al., 2015). Microglial activation
is consistently detected in the motor cortex however one study
also detected an increase in the dorsolateral prefrontal cortex
and thalamus (Turner et al., 2004). Interestingly, microgliosis
appears to associate with disease severity (Turner et al., 2004;
Brettschneider et al., 2012; Zürcher et al., 2015), with a recent
study suggesting microgliosis is specifically associated with rapid
disease progression (Gorter et al., 2018). Taking a data-driven
approach, another recent work uncovered networks of genes
that associate with motor neuron pathology in human ALS
brain. The study found that most genes within the top scoring
network, are expressed in microglia (Cooper-Knock et al., 2017).
Furthermore, TREM2 levels in the cerebrospinal fluid (CSF)
of ALS patients was higher than controls and TREM2 levels
positively correlated with disease duration in late stage ALS
(Cooper-Knock et al., 2017). This supports previous work which
found an increased expression of TREM2 mRNA in human and
SOD1 mouse spinal cord, and also implicated a rare variant in
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TREM2 (p.R47H) as a risk factor for developing ALS (Cady
et al., 2014). Therefore, it is clear that microglia have an
important role to play in ALS pathogenesis (Geloso et al., 2017),
but what effect are microglia having on surrounding neurons?
An intricate mouse study utilizing cell-type specific expression
of mutant SOD1 G93A, placed microglia in a central role
for mediating ALS progression. Removing mutant SOD1 from
microglia, thus returning them to a wild-type state, had no
effect on disease onset, but significantly slowed late stage
progression (Boillée et al., 2006). This is supported by recent
work (Frakes et al., 2014) showing that a toxic microglial gain
of function exerts a pathological effect on neurons in ALS. Our
recent work has uncovered a potential mechanism by which
activated, inflammatory microglia may exert degenerative effects
on neurons. TDP-43 is the main pathological hallmark of ALS,
with protein aggregates found in almost 100% of ALS cases
(Neumann et al., 2006; Ling et al., 2013). Debate surrounds
whether this leads to a pathological loss of normal function or
a toxic gain of function, however, when TDP-43 is specifically
knocked-out of microglial cells in mice, we found that they
convert to a hyper-phagocytic phenotype and ingest surrounding
synapses (Paolicelli et al., 2017). This links TDP-43 pathology to
microglial activation and synapse loss. In human ALS brain, the
presence of TDP-43 pathology in the frontal cortex is associated
with a higher burden of microglial activity as evidenced by
increased CD68 expression (Brettschneider et al., 2012; Paolicelli
et al., 2017). Furthermore, the presence of TDP-43 in the frontal
cortex was associated with lower synapse number in one study
(Henstridge et al., 2018) and cognitive impairment in another
(Brettschneider et al., 2012). Taken together, these studies place
TDP-43 pathology and activated microglia at the sites of synapse
loss in the ALS brain, resulting in a breakdown of neuronal
function and clinical manifestation of ALS.
The evidence above clearly states that synapse loss is a
prominent feature in human ALS brain and in diverse ALS
models. However, does a similar synaptic breakdown occur
around lower motor neurons within the spinal cord? A number
of early studies assessing synaptic coverage of spinal motor
neurons in human post mortem tissue described synapse loss and
altered morphology in remaining synapses (Matsumoto et al.,
1994; Sasaki and Maruyama, 1994a,b; Ince et al., 1995). Similar
findings are evident in the SOD1 G93A mouse model, with
decreased synapses onto motor neurons in the spinal cord and
decreased spine density of spinal motor neurons (Zang et al.,
2005; Fogarty et al., 2017). In the same mouse model, another
study found a decrease in total synapse number onto brainstem
motor neurons that manifested as a small increase in excitatory
synapses and a larger decrease of inhibitory terminals (Sunico
et al., 2011). Taken together it is clear that synapses are lost in the
brainstem and spinal cord in ALS. At approximately the same
time as spines are being lost in the SOD1 G93A mouse model,
microglia are proliferating in the rat SOD1 G93A model (Graber
et al., 2010). However, to the best of our knowledge no studies to
date have assessed whether microglia may be stripping synapses
in the spinal cord.
A recent study has found that microglia in the spinal
cord may play a neuroprotective role. When human TDP-43
was over-expressed exclusively in neurons, microgliosis in the
spinal cord was mild, but when the TDP-43 was switched
off with doxycycline treatment, microglia became inflamed,
proliferated and selectively engulfed neuronally-derived TDP-43
(Spiller et al., 2018). This has been recently confirmed in a
zebrafish model of human TDP-43 over-expression, in which
microglia actively phagocytose degenerating spinal cord neurons
expressing TDP-43 (Svahn et al., 2018). Taken together, these
studies suggest that TDP-43 in stressed neurons may act as a
signal to attract phagocytic microglia to clear away aggregated
TDP-43. With this in mind, it is interesting to note that TDP-43
aggregates have been observed in human synapses (Henstridge
et al., 2018) and may act as a microglial ‘‘eat me’’ signal in the
same way complement appears to in AD.
Microglia can also exert indirect effects on neuronal and
synaptic function by the release of numerous signalingmolecules.
There is a wealth of literature describing the increased expression
of proinflammatory mediators in ALS models and patients,
ranging from elevated blood levels of TNF-a in human blood
to increased chemokine MCP-1 expression in SOD1 mouse
models (reviewed in Philips and Robberecht, 2011). Many of
these excreted molecules can directly affect neuronal physiology,
such as NO, reactive oxygen species (ROS) and cytokines (Henkel
et al., 2009), further supporting a role for microglia ALS-related
synapse dysfunction.
Astrocyte-Dependent Loss of Central
Synapses in ALS
Glutamate is the major excitatory neurotransmitter in the
brain and its levels need to be tightly controlled at the
synapse to prevent excitotoxicity. Astrocytes play a major
role by actively taking up excess glutamate using glutamate
transporters, EEAT1 and EEAT2 (also known as GLAST and
GLT-1, respectively). In SOD1 models, GLT-1 levels decrease
as disease progresses (Bruijn et al., 1997) and this finding is
consistent in human ALS spinal cord and brain (Rothstein et al.,
1995). These early studies suggest that a failure in astrocytic
control of synaptic glutamate may result in excitotoxicity and
network imbalance, supported by a study that knocked out
glial GLT-1 using oligonucleotides and discovered that animals
developed a progressive motor paralysis (Rothstein et al., 1996).
Interestingly, crossing the SOD G93A mouse with an EAAT2
over-expressing mouse delayed axonal dystrophy and motor
neuron loss but did not affect onset of paralysis or life span
(Guo et al., 2003). Despite this less than positive outcome, a
pharmacological approach (beta-lactam antibiotic, ceftriaxone)
to stimulate GLT-1 expression in SOD1 G93A mice at symptom
onset, led to delayed loss of muscle strength and body weight and
prolonged life by 10 days (Rothstein et al., 2005). Ceftriaxone was
tested in a recent clinical trial and provided some excitement after
a successful Phase 2, however it failed to show clinical efficacy in
Phase 3 (Cudkowicz et al., 2014). It was not determined if the
drug affected EAAT2 expression or function in the participants,
so further work is required to assess the value in targeting glial
glutamate transporters in ALS. Astrocytes also play an important
trophic role through the uptake of glucose from the blood stream,
which they convert into lactate and pass to neurons for the
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generation of glutamate (Pellerin and Magistretti, 1994; Pellerin
et al., 1998). Lactate is shuttled from the astrocyte to the neuron
in a pathway requiring the glutamate transporters mentioned
above, however pre-symptomatic SOD1 G93A mice have a
significantly lower amount of lactate in spinal cord homogenates
and a decreased expression of GLAST (Ferraiuolo et al., 2011).
This suggests a disruption in the astrocyte-neuron lactate shuttle,
potentially rendering the neurons hypometabolic.
Small heat shock proteins (HSPBs) are important chaperones
that reduce protein misfolding and aid in misfolded protein
degradation. A recent study has found that in human ALS
spinal cord, rapidly progressing disease was associated with
increased HSPB5 and HSPB8 in astrocytes (Gorter et al.,
2018). Furthermore, a recent rat model with restricted mutant
human TDP-43 (M337V) expression in astrocytes, displayed a
progressive paralysis due to loss of motor neurons in the spinal
cord (Tong et al., 2013). This strongly supports an important
role for glia-derived toxicity in ALS. These studies suggest that
astrocytes may become overwhelmed with misfolded protein
stressors in ALS, which could affect their trophic support of
neurons and synapses. While it is clear that astrocytes have
an important role to play in the synaptic pathology of ALS,
there are currently no studies that we are aware of showing
astrocytic ingestion of synaptic terminals. It will be important to
discover if astrocytes are restricted to indirect effects on synaptic
dysfunction or whether they can physically strip synapses and
dystrophic dendrites as observed in other diseases.
Cross-talk between astrocytes and microglia also appear to
play a critical role in ALS pathogenesis. In the SOD1 G93A
mouse, specific knock out of SOD1 G93A from astrocytes, thus
reverting them back to wild-type, had no effect on ALS onset but
significantly delayed microglial activation and slowed late-stage
disease (Yamanaka et al., 2008). This suggests that in ALS not
only do microglia and astrocytes affect neuronal physiology
alone, they also regulate the function of one another. Figure 4
shows a schematic representation of microglial and astrocytic
roles in synapse loss in ALS.
Glia-Dependent Loss of Peripheral
Synapses in ALS
The NMJ exists as a tripartite structure, consisting of the motor
nerve ending, the postsynaptic muscle cell and non-myelinating
perisynaptic Schwann cells (PSCs; Ko and Robitaille, 2015).
These specialized glial cells are critical for the maintenance
and remodeling of adult NMJs, actively phagocytosing damaged
nerve terminals and guiding regenerating nerves to their correct
target (Ko and Robitaille, 2015). Active uptake of degenerating
axonal components by Schwann cells involves the initial
formation of ‘‘axosomes,’’ aggregates of synaptic proteins and
membrane fragments that are released by the axonal tip (Bishop
et al., 2004). Phagocytic behavior of PSCs is induced by signals
released from degenerating motor neuron axons, resulting in
engulfment of synaptic terminals at the NMJ (Duregotti et al.,
2015). Interestingly, in a toxin-induced neuropathy model, the
toxic signals (H2O2, mitochondrial DNA and cytochrome C)
are released from mitochondria within the degenerating motor
nerves, supporting the role of mitochondrial dysfunction in
ALS (Duregotti et al., 2015; Smith et al., 2017). Furthermore,
the expression of numerous receptors and signaling molecules
involved in regulating PSC activity is under the control of
the RNA-binding protein TDP-43 (Narayanan et al., 2013),
suggesting that TDP-43 dysfunction can significantly impact the
activity of Schwann cells at the NMJ.
Given the important role of the complement system in
synapse loss in AD, it is interesting to note that components of
the complement system are found at the NMJ in SOD1 mouse
models and human tissue (Heurich et al., 2011; Bahia El
Idrissi et al., 2016). It will be interesting to discover if
these proteins tag the synaptic terminals for engulfment,
in a similar glial-dependent process as described in AD
above. Paradoxically, a recent study has shown that C1q
deletion exacerbates disease progression and synapse loss in a
SOD1 mouse model, revealing that further study is required
to understand the role of complement at peripheral synaptic
function (Lobsiger et al., 2013).
While these intriguing studies provide a glimpse of the normal
function of PSCs, little is known about their role in disease. For
example, it would be important to know if disease-associated
changes in PSC activity resulted in aberrant synapse loss or
whether their trophic role is disrupted in disease, leading to
pathogenic processes.
MULTIPLE SCLEROSIS
MS is an autoimmune disease characterized by oligodendroglial
dysfunction (Kotter et al., 2006; Miron et al., 2013) and T-cell
driven inflammation (Korn et al., 2007; Aggelakopoulou et al.,
2016), resulting in demyelination of gray and white matter
tracts. Loss of the myelin sheath makes axons less capable of
propagating electrical signals to the synapse and renders them
more vulnerable to degeneration. Typically, affected individuals
present with motor deficits but signs of cognitive decline are
also evident in some patients (Rao et al., 1991; Chiaravalloti
and DeLuca, 2008). Due to the demyelinating nature of MS and
because the white matter is myelin-rich, changes in the gray
matter have been largely over-looked, particularly in respect to
synapses. Dendritic cortical spine loss, independent of cortical
demyelination and axon loss, has emerged as a pathological
feature of some MS patients (Nistico et al., 2014; Jürgens et al.,
2016), which may explain the cognitive deficits (Di Filippo et al.,
2018). The role of microglia and astrocytes as active players in
MS-associated synaptic stripping (Figure 5) has been implied by
multiple post-mortem studies but quantitative and mechanistic
evidence is still elusive.
Microglial and Astrocyte Contribution to
Synapse Loss in MS
Hippocampal microgliosis is a common feature in MS models as
well as in human post-mortem samples, highlighting microglia
yet again as a potential driver of synaptic loss in disease.
Primarily, there are fewer pre-synaptic terminals in demyelinated
MS cases (MS-D) compared to myelinated (MS-M) and control
cases in various regions of the hippocampus, including CA3 and
CA1 (Michailidou et al., 2015). Moreover, the researchers found
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FIGURE 4 | Pathophysiology of amyotrophic lateral sclerosis (ALS). ALS is characterized by the breakdown of motor neurons in the motor cortex and spinal cord.
Gliosis and cortical hyperexcitability are early features of the ALS brain and aggregates of TDP-43 are found in almost all patients. TDP-43 has been found at human
synapses in ALS and the removal of TDP-43 from microglia leads to hyperphagocytic cells that engulf synapses. Microglia have been shown to engulf
neuronally-derived TDP43. Interestingly, synapse loss is an early feature of ALS and observed in both the central and peripheral nervous systems.
that the levels of C1q and C3 are increased in the MS-D
cases, and have shown, but not quantified, activated microglia
containing pre-synaptic elements, suggesting that complement
molecules—once again—may act as a synapse removal tag.
C3d-expressingmicroglial clusters are seen in chronicMS lesions
rather than the acute phases of demyelination, indicating C3d
may not play a role in the initial synaptic degeneration seen
in MS-D. Moreover, in the gray matter of MS post-mortem
cases, C1q-positive neurons show dysmorphic nuclei, typical
of cell stress, when adjacent to activated microglia clusters
(Watkins et al., 2016). Together, these studies suggest a model
in which C1q may act as a tag for early synaptic engulfment
in MS, while neuronal C3d is internalized by microglia during
phagocytosis of degenerating neuronal and synaptic debris in
later phases of the disease. In addition, other members of the
classical complement cascade need to be considered. Specifically,
administration of oligonucleotides against C6 partially rescued
the synaptophysin depletion found in experimental autoimmune
encephalomyelitis (EAE) mouse model for MS. Reduction in
C6 also led to decreases in the levels of IL-1β, microgliosis,
myelin damage, and C9 of the membrane attack complex (MAC;
Michailidou et al., 2018). Interestingly, C9 showed a strong
negative correlation to synaptophysin, meaning high levels of
C9 correlate with lower levels of pre-synaptic terminals. Given
that the MAC can activate subsequent pathological mediators
like the NLRP3 inflammasome in microglia (Laudisi et al., 2013),
which allows maturation and release of IL-1β (Jo et al., 2016),
it makes sense that there are lowers levels of inflammation and
gliosis when C6 is inhibited. Furthermore, it has been previously
discussed in the context of AD that other pro-inflammatory
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FIGURE 5 | Pathophysiology of multiple sclerosis (MS). While myelin loss is a central feature of MS pathology, it is accompanied by neurodegeneration, gliosis and
immune cell (B-cells and T-cells) infiltration. Release of pro-inflammatory mediators and disrupted glutamate handling by glial cells leads to a toxic neuronal milieu.
Furthermore, there is evidence that microglia are involved in complement-dependent synapse engulfment.
cytokines secreted by microglia have synaptotoxic effects,
providing an alternative pathway to non-contact dependent
synapse loss. Astrocytes can also contribute to glutamate
excitotoxicity in MS as they reduce the levels of their glutamate
transporters, EAAT1 and EAAT2, in MS-D lesions (Dutta et al.,
2011), allowing excess levels of glutamate to surround synapses.
E/I Imbalance in MS and Possible
Implication of Glia
Evidence of E/I imbalance has been reported in MS animal
models, particularly the EAE model. Electrophysiological
experiments have shown decreased excitatory post-synaptic
potentials (EPSPs) in the CA1 of the hippocampus and
impaired LTP in EAE mice, leading to cognitive impairments
mediated by IL-1β driven inflammation (Kim et al., 2012;
Di Filippo et al., 2013). This functional impairment may
arise due to the downregulation of GluN2B NMDAR
subunits in EAE mice. In contrast, there is evidence for
inflammation-associated increase of LTP and reduction of
LTD in EAE mice, displaying overall circuit hyperexcitation
(Nistico et al., 2014). In favor of this, a magnetic resonance
spectroscopy study found increased levels of glutamate in
demyelinated brain areas of MS patients (Srinivasan et al.,
2005), implicating excitatory imbalance as a pathological
substrate for myelin damage, preceding synapse loss (Dutta
et al., 2011). Specifically, oligodendroglia are vulnerable to
glutamate excitotoxicity as they express NMDARs (Pérez-
Otaño et al., 2016) which are required for activity-dependent
myelination and plasticity (Lundgaard et al., 2013). Therefore,
initial hyperexcitability could result in oligodendroglial
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dysfunction and demyelination, ultimately rendering synapses
weaker and more vulnerable to elimination, leading to later
LTP impairments.
However, other studies have reported synapse reduction
occurring independently of demyelination (Jürgens et al., 2016;
Albert et al., 2017).
Researchers also found increased, rather than decreased, spine
density in the somatosensory cortex of EAE mice, associated
with increased VGLUT1 levels and disrupted PV+ interneuron
connectivity (Potter et al., 2016). The altered excitatory-
inhibitory balance in the cortex of these mice was associated with
increased density of Iba1+ microglia, however no evidence of
cause-effect was reported (Potter et al., 2016).
The synaptic terminals assessed in the above MS and EAE
studies are exclusively pre-synaptic with no distinction of
excitatory or inhibitory nature. Loss of inhibitory signaling
causes E/I imbalance, which has already been described here
in the context of dementias but applies to MS as well. Indeed,
GABA levels are reduced in the CSF of patients with MS,
indicating decreased inhibition (Manyam et al., 1980). More
recently, RNA sequencing from gray matter of motor cortices
in MS patients showed downregulation of multiple genes
that are critical to interneuron function (Dutta et al., 2006).
Namely, there was downregulation of GAD67, an enzyme
required for GABA synthesis pre-synaptically, and of the GABA
receptor subunits α1 and β3 which are essential for GABA
function post-synaptically. Furthermore, parvalbumin (PV) and
cholecystokinin (CCK) levels were found to be lower in MS than
controls, with PV-positive interneurons reduced by 30% in MS
gray matter (Dutta et al., 2006).
Reduction of axosomatic synaptic terminals was recently
reported in the cerebellum of MS patients, associated
with increased levels of reactive astrocytes and microglia,
specifically in the dentate nucleus (Albert et al., 2017). In this
study, ultrastructural examination by electron microscopy
revealed evidence for astrocyte-mediated synaptic stripping
(Albert et al., 2017).
Altogether, these findings point toward a consistent alteration
in the E/I balance in MS and encourage further investigation to
better elucidating the role of glia mediated-synapse loss.
CONCLUSION
Here, we have summarized the contributions of glial cells
in some of the most common neurodegenerative diseases,
highlighting evidence for their role in synapse remodeling. In
disease, glia-mediated synaptic refinement likely represents an
attempt to counteract network dysfunction occurring in the
early stages of the disease. In this scenario, glia selectively
remove excitatory or inhibitory connections in specific brain
regions, to compensate for disease-associated changes in synaptic
input. On the other hand, intrinsic dysfunction of glia cells,
due for instance to genetic mutations, could also play a
critical causative role in the pathogenesis of the diseases,
acting as a primary trigger for E/I imbalance, by inducing
excessive synaptic pruning (Figure 6). It is tempting to speculate
that similar mechanisms could occur in response to shifts
FIGURE 6 | Glial Influence on excitatory/inhibitory balance. Under
physiological conditions, glial cells play important roles in the control of
neuronal physiology, resulting in a well-controlled balance of
excitatory/inhibitory neuronal networks. However, under pathological
conditions as described in some of the diseases here, glial cells become
hyperactive and damage surrounding neurons. This results in a dramatic tip
of the balance depending on whether excitatory or inhibitory cells are
disproportionally affected in the network.
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in E/I balance in the developing brain, where glia-mediated
synaptic alterations may lead to long lasting structural and
functional defects, thus promoting the risk of developing
psychiatric disorders and depression later in life (Durieux
et al., 2015; Rial et al., 2015). Thus, deeper insight into the
process of synapse remodeling mediated by glia cells, both
in physiological and pathological conditions, will be essential
for designing effective therapeutics to prevent, or at least halt
synapse elimination. Such therapeutic interventions include an
attenuation of the microglial response in AD pathology. For
example, in two separate models of AD, the APPswe/PS1 and
the 5xFAD, inhibiting the colony stimulating factor-1 receptor
(CSF1R) markedly reduced microglial proliferation, rescuing
synapse loss and cognitive deficits (Olmos-Alonso et al., 2016;
Spangenberg et al., 2016). Importantly, in neither of these
studies did pharmacological inhibition of microglia influence
Aβ-plaque load, suggesting that microglial activation in AD can
be synaptotoxic, via non-Aβ mediated mechanisms. However,
whether this synaptic and cognitive rescue was due to attenuating
microglial driven inflammation is unclear. Microglial neurotoxic
and synaptotoxic cytokine release in prodromal stages of the
disease is likely to coincide with complement deposition and
aberrant phagocytosis. Complement molecules deposited at
synapses have been reported to be work as a powerful ‘‘eat me’’
signal in several distinct neurodegenerative disorders. However,
synapse elimination in pathological contexts could also be seen
as a beneficial process, at least in the initial stages, aimed
at re-establishing the E/I balance. Critical information will
be provided by clinical trials currently testing a humanized
anti-C1q antibody in neurodegeneration, after its safety was
recently proven in both animal models and human cohorts
(Lansita et al., 2017).
Given that early synapse loss is a common phenotype in many
neurodegenerative diseases, it raises the exciting possibility that
a greater understanding of glia-mediated synapse loss may lead
to a single therapeutic strategy that targets many of the world’s
most devastating diseases.
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